Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.
Noguchi P, et al. Characterization of WiDr: a human colon carcinoma cell line. In Vitro 15: 401-408, 1979. PubMed: 90012
Sugarman BJ, et al. Recombinant human tumor necrosis factor-alpha: effects on proliferation of normal and transformed cells in vitro. Science 230: 943-945, 1985. PubMed: 3933111
Chen TR, et al. WiDr is a derivative of another colon adenocarcinoma cell line, HT-29. Cancer Genet. Cytogenet. 27: 125-134, 1987. PubMed: 3472642
Smith SG, et al. Cytotoxicity of antifolate inhibitors of thymidylate and purine synthesis to WiDr colonic carcinoma cells. Cancer Res. 53: 5697-5706, 1993. PubMed: 8242626
Rodrigues NR, et al. p53 mutations in colorectal cancer. Proc. Natl. Acad. Sci. USA 87: 7555-7559, 1990. PubMed: 1699228
Petricciani JC, et al. A comparison of three in vivo assays for cell tumorigenicity. Cancer Res. 34: 105-108, 1974. PubMed: 4203458
Tsuboi KK, Kwong LK. Antiproliferative agents and differential survival between normal and cancer cells. Cancer Res. 38: 3745-3750, 1978. PubMed: 698934
Noguchi PD, et al. Chick embryonic skin as a rapid organ culture assay for cellular neoplasia. Science 199: 980-983, 1978. PubMed: 203036
Tsao H, et al. Novel mutations in the p16/CDKN2A binding region of the Cyclin-dependent Kinase-4 gene. Cancer Res. 58: 109-113, 1998. PubMed: 9426066
Olive PL, Banath JP. Multicell spheroid response to drugs predicted with the comet assay. Cancer Res. 57: 5528-5533, 1997. PubMed: 9407963
Tumors developed within 21 days at 100% frequency (5/5) in nude mice inoculated subcutaneously with 10(7) cells
